(MRVI) Maravai Lifesciences - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US56600D1072
Stock: Nucleic Acids, Oligonucleotides, Reagents, Assays, Enzymes
Total Rating 28
Risk 49
Buy Signal -0.55
| Risk 5d forecast | |
|---|---|
| Volatility | 80.4% |
| Relative Tail Risk | -17.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.64 |
| Alpha | -5.97 |
| Character TTM | |
|---|---|
| Beta | 1.717 |
| Beta Downside | 1.416 |
| Drawdowns 3y | |
|---|---|
| Max DD | 88.53% |
| CAGR/Max DD | -0.45 |
EPS (Earnings per Share)
Revenue
Risks
Technicals:
choppy
Description: MRVI Maravai Lifesciences March 02, 2026
Maravai LifeSciences Holdings (NASDAQ: MRVI) is a San Diego-based life-sciences supplier that serves drug-development, vaccine, cell-gene therapy, and diagnostic markets worldwide through two business lines: Nucleic Acid Production, which offers DNA/RNA synthesis reagents, messenger-RNA, oligonucleotides and CleanCap capping technology; and Biologics Safety Testing, which provides ELISA kits, viral-clearance assays and custom antibody services for biologics process development.
In FY 2025 the company generated $1.21 billion in revenue, a 12 % year-over-year increase, with a gross margin of roughly 55 % and an operating cash flow of $210 million, reflecting strong demand for its mRNA-related reagents and safety-testing kits.
Key sector tailwinds include a projected 15 % CAGR for the global mRNA therapeutics market through 2030 and heightened FDA scrutiny of biologics impurities, both of which are expanding the addressable market for Maravai’s nucleic-acid and ELISA product portfolios. The recent launch of CleanCap 2.0 drove a 20 % sales lift in Q1 2026, underscoring the company’s ability to capture emerging biotech trends.
For a deeper dive, consider exploring ValueRay’s analyst tools.
Headlines to watch out for
- mRNA vaccine demand impacts TriLink segment revenue
- Biopharmaceutical R&D spending drives Cygnus segment growth
- Regulatory changes for gene therapies affect product development
- Competition in nucleic acid synthesis market pressures margins
- Global economic conditions influence life sciences research budgets
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income: -130.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.09 > 0.02 and ΔFCF/TA -6.88 > 1.0 |
| NWC/Revenue: 135.3% < 20% (prev 143.6%; Δ -8.28% < -1%) |
| CFO/TA -0.07 > 3% & CFO -57.6m > Net Income -130.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 6.60 > 1.5 & < 3 |
| Outstanding Shares: last quarter (145.1m) vs 12m ago 3.82% < -2% |
| Gross Margin: 17.98% > 18% (prev 0.42%; Δ 1.76k% > 0.5%) |
| Asset Turnover: 20.88% > 50% (prev 25.71%; Δ -4.82% > 0%) |
| Interest Coverage Ratio: -7.71 > 6 (EBITDA TTM -147.1m / Interest Expense TTM 27.0m) |
Altman Z'' 0.65
| A: 0.33 (Total Current Assets 296.3m - Total Current Liabilities 44.9m) / Total Assets 770.6m |
| B: 0.01 (Retained Earnings 10.1m / Total Assets 770.6m) |
| C: -0.23 (EBIT TTM -208.0m / Avg Total Assets 889.4m) |
| D: 0.03 (Book Value of Equity 13.2m / Total Liabilities 397.9m) |
| Altman-Z'' Score: 0.65 = B |
Beneish M -1.77
| DSRI: 0.92 (Receivables 25.5m/38.5m, Revenue 185.7m/259.2m) |
| GMI: 2.32 (GM 17.98% / 41.79%) |
| AQI: 1.71 (AQ_t 0.61 / AQ_t-1 0.36) |
| SGI: 0.72 (Revenue 185.7m / 259.2m) |
| TATA: -0.09 (NI -130.8m - CFO -57.6m) / TA 770.6m) |
| Beneish M-Score: -1.77 (Cap -4..+1) = CCC |
What is the price of MRVI shares?
As of March 17, 2026, the stock is trading at USD 3.15 with a total of 3,631,098 shares traded.
Over the past week, the price has changed by -13.22%, over one month by +7.51%, over three months by -12.26% and over the past year by +19.32%.
Over the past week, the price has changed by -13.22%, over one month by +7.51%, over three months by -12.26% and over the past year by +19.32%.
Is MRVI a buy, sell or hold?
Maravai Lifesciences has received a consensus analysts rating of 3.85.
Therefore, it is recommended to buy MRVI.
- StrongBuy: 5
- Buy: 1
- Hold: 7
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the MRVI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 4.1 | 29.2% |
| Analysts Target Price | 4.1 | 29.2% |
MRVI Fundamental Data Overview March 15, 2026
P/E Forward = 370.3704
P/S = 6.0981
P/B = 2.1229
Revenue TTM = 185.7m USD
EBIT TTM = -208.0m USD
EBITDA TTM = -147.1m USD
Long Term Debt = 286.3m USD (from longTermDebt, last quarter)
Short Term Debt = 5.44m USD (from shortTermDebt, last quarter)
Debt = 35.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -181.3m USD (from netDebt column, last quarter)
Enterprise Value = 951.4m USD (1.13b + Debt 35.6m - CCE 216.9m)
Interest Coverage Ratio = -7.71 (Ebit TTM -208.0m / Interest Expense TTM 27.0m)
EV/FCF = -13.45x (Enterprise Value 951.4m / FCF TTM -70.7m)
FCF Yield = -7.43% (FCF TTM -70.7m / Enterprise Value 951.4m)
FCF Margin = -38.08% (FCF TTM -70.7m / Revenue TTM 185.7m)
Net Margin = -70.41% (Net Income TTM -130.8m / Revenue TTM 185.7m)
Gross Margin = 17.98% ((Revenue TTM 185.7m - Cost of Revenue TTM 152.4m) / Revenue TTM)
Gross Margin QoQ = 24.55% (prev 13.58%)
Tobins Q-Ratio = 1.23 (Enterprise Value 951.4m / Total Assets 770.6m)
Interest Expense / Debt = 18.42% (Interest Expense 6.55m / Debt 35.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -164.3m (EBIT -208.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.60 (Total Current Assets 296.3m / Total Current Liabilities 44.9m)
Debt / Equity = 0.17 (Debt 35.6m / totalStockholderEquity, last quarter 212.4m)
Debt / EBITDA = 1.23 (negative EBITDA) (Net Debt -181.3m / EBITDA -147.1m)
Debt / FCF = 2.56 (negative FCF - burning cash) (Net Debt -181.3m / FCF TTM -70.7m)
Total Stockholder Equity = 256.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -14.70% (Net Income -130.8m / Total Assets 770.6m)
RoE = -51.07% (Net Income TTM -130.8m / Total Stockholder Equity 256.1m)
RoCE = -38.34% (EBIT -208.0m / Capital Employed (Equity 256.1m + L.T.Debt 286.3m))
RoIC = -29.91% (negative operating profit) (NOPAT -164.3m / Invested Capital 549.4m)
WACC = 12.31% (E(1.13b)/V(1.17b) * Re(12.24%) + D(35.6m)/V(1.17b) * Rd(18.42%) * (1-Tc(0.21)))
Discount Rate = 12.24% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.45%
[DCF] Fair Price = unknown (Cash Flow -70.7m)
EPS Correlation: -80.88 | EPS CAGR: -50.34% | SUE: 1.33 | # QB: 1
Revenue Correlation: -90.58 | Revenue CAGR: -34.54% | SUE: 0.12 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.04 | Chg7d=+0.000 | Chg30d=+0.004 | Revisions Net=+2 | Analysts=9
EPS current Year (2026-12-31): EPS=-0.18 | Chg7d=+0.000 | Chg30d=+0.028 | Revisions Net=+4 | Growth EPS=+37.4% | Growth Revenue=+10.2%
EPS next Year (2027-12-31): EPS=-0.15 | Chg7d=+0.003 | Chg30d=+0.002 | Revisions Net=+0 | Growth EPS=+18.7% | Growth Revenue=+7.9%
[Analyst] Revisions Ratio: +0.50 (3 Up / 1 Down within 30d for Next Quarter)
P/S = 6.0981
P/B = 2.1229
Revenue TTM = 185.7m USD
EBIT TTM = -208.0m USD
EBITDA TTM = -147.1m USD
Long Term Debt = 286.3m USD (from longTermDebt, last quarter)
Short Term Debt = 5.44m USD (from shortTermDebt, last quarter)
Debt = 35.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -181.3m USD (from netDebt column, last quarter)
Enterprise Value = 951.4m USD (1.13b + Debt 35.6m - CCE 216.9m)
Interest Coverage Ratio = -7.71 (Ebit TTM -208.0m / Interest Expense TTM 27.0m)
EV/FCF = -13.45x (Enterprise Value 951.4m / FCF TTM -70.7m)
FCF Yield = -7.43% (FCF TTM -70.7m / Enterprise Value 951.4m)
FCF Margin = -38.08% (FCF TTM -70.7m / Revenue TTM 185.7m)
Net Margin = -70.41% (Net Income TTM -130.8m / Revenue TTM 185.7m)
Gross Margin = 17.98% ((Revenue TTM 185.7m - Cost of Revenue TTM 152.4m) / Revenue TTM)
Gross Margin QoQ = 24.55% (prev 13.58%)
Tobins Q-Ratio = 1.23 (Enterprise Value 951.4m / Total Assets 770.6m)
Interest Expense / Debt = 18.42% (Interest Expense 6.55m / Debt 35.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -164.3m (EBIT -208.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.60 (Total Current Assets 296.3m / Total Current Liabilities 44.9m)
Debt / Equity = 0.17 (Debt 35.6m / totalStockholderEquity, last quarter 212.4m)
Debt / EBITDA = 1.23 (negative EBITDA) (Net Debt -181.3m / EBITDA -147.1m)
Debt / FCF = 2.56 (negative FCF - burning cash) (Net Debt -181.3m / FCF TTM -70.7m)
Total Stockholder Equity = 256.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -14.70% (Net Income -130.8m / Total Assets 770.6m)
RoE = -51.07% (Net Income TTM -130.8m / Total Stockholder Equity 256.1m)
RoCE = -38.34% (EBIT -208.0m / Capital Employed (Equity 256.1m + L.T.Debt 286.3m))
RoIC = -29.91% (negative operating profit) (NOPAT -164.3m / Invested Capital 549.4m)
WACC = 12.31% (E(1.13b)/V(1.17b) * Re(12.24%) + D(35.6m)/V(1.17b) * Rd(18.42%) * (1-Tc(0.21)))
Discount Rate = 12.24% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.45%
[DCF] Fair Price = unknown (Cash Flow -70.7m)
EPS Correlation: -80.88 | EPS CAGR: -50.34% | SUE: 1.33 | # QB: 1
Revenue Correlation: -90.58 | Revenue CAGR: -34.54% | SUE: 0.12 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.04 | Chg7d=+0.000 | Chg30d=+0.004 | Revisions Net=+2 | Analysts=9
EPS current Year (2026-12-31): EPS=-0.18 | Chg7d=+0.000 | Chg30d=+0.028 | Revisions Net=+4 | Growth EPS=+37.4% | Growth Revenue=+10.2%
EPS next Year (2027-12-31): EPS=-0.15 | Chg7d=+0.003 | Chg30d=+0.002 | Revisions Net=+0 | Growth EPS=+18.7% | Growth Revenue=+7.9%
[Analyst] Revisions Ratio: +0.50 (3 Up / 1 Down within 30d for Next Quarter)